Literature DB >> 19890064

Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7.

Carole Bourquin1, Laura Schmidt, Anna-Lisa Lanz, Bettina Storch, Cornelia Wurzenberger, David Anz, Nadja Sandholzer, Ralph Mocikat, Michael Berger, Hendrik Poeck, Gunther Hartmann, Veit Hornung, Stefan Endres.   

Abstract

RNA oligonucleotides containing immune-activating sequences promote the development of cytotoxic T cell and B cell responses to Ag. In this study, we show for the first time that immunostimulatory RNA oligonucleotides induce a NK cell response that prevents growth of NK-sensitive tumors. Treatment of mice with immunostimulatory RNA oligonucleotides activates NK cells in a sequence-dependent manner, leading to enhanced IFN-gamma production and increased cytotoxicity. Use of gene-deficient mice showed that NK activation is entirely TLR7-dependent. We further demonstrate that NK activation is indirectly induced through IL-12 and type I IFN production by dendritic cells. Reconstitution of TLR7-deficient mice with wild-type dendritic cells restores NK activation upon treatment with immunostimulatory RNA oligonucleotides. Thus, by activating both NK cells and CTLs, RNA oligonucleotides stimulate two major cellular effectors of antitumor immunity. This dual activation may enhance the efficacy of immunotherapeutic strategies against cancer by preventing the development of tumor immune escape variants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890064     DOI: 10.4049/jimmunol.0901594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea.

Authors:  Gregory M Frank; Kristine-Ann G Buela; Dawn M Maker; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2011-12-30       Impact factor: 5.422

Review 2.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.

Authors:  Abbi L Engel; Gregory E Holt; Hailing Lu
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

3.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.

Authors:  Christian Hotz; Marina Treinies; Ines Mottas; Laurin C Rötzer; Anne Oberson; Lorenzo Spagnuolo; Maurizio Perdicchio; Thibaud Spinetti; Tina Herbst; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

4.  TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function.

Authors:  Thibaud Spinetti; Lorenzo Spagnuolo; Inès Mottas; Chiara Secondini; Marina Treinies; Curzio Rüegg; Christian Hotz; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

5.  A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Authors:  Gabriela Maria Wiedemann; Severin Johannes Jacobi; Michael Chaloupka; Angelina Krächan; Svetlana Hamm; Stefan Strobl; Roland Baumgartner; Simon Rothenfusser; Peter Duewell; Stefan Endres; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2016-05-31       Impact factor: 8.110

Review 6.  The Yin and Yang of Toll-like receptors in cancer.

Authors:  J-P Pradere; D H Dapito; R F Schwabe
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

7.  RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection.

Authors:  Christoph Coch; Jan Phillip Stümpel; Vanessa Lilien-Waldau; Dirk Wohlleber; Beate M Kümmerer; Isabelle Bekeredjian-Ding; Georg Kochs; Natalio Garbi; Stephan Herberhold; Christine Schuberth-Wagner; Janos Ludwig; Winfried Barchet; Martin Schlee; Achim Hoerauf; Friedrich Bootz; Peter Staeheli; Gunther Hartmann; Evelyn Hartmann
Journal:  Mol Ther       Date:  2017-07-08       Impact factor: 11.454

8.  Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.

Authors:  Christian Hotz; Carole Bourquin
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

9.  Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

Review 10.  The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Authors:  Marisa Rosso; Miguel Muñoz; Michael Berger
Journal:  ScientificWorldJournal       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.